Literature DB >> 11108928

B cells and antibodies in CNS demyelinating disease.

A H Cross1, J L Trotter, J Lyons.   

Abstract

There is much evidence to implicate B cells, plasma cells, and their products in the pathogenesis of MS. Despite unequivocal evidence that the animal model for MS, EAE, is initiated by myelin-specific T cells, there is accumulating evidence of a role for B cells, plasma cells, and their products in EAE pathogenesis. The role(s) played by B cells, plasma cells, and antibodies in CNS inflammatory demyelinating diseases are likely to be multifactorial and complex, involving distinct and perhaps opposing roles for B cells versus antibody.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11108928     DOI: 10.1016/s0165-5728(00)00409-4

Source DB:  PubMed          Journal:  J Neuroimmunol        ISSN: 0165-5728            Impact factor:   3.478


  62 in total

Review 1.  Maintenance and loss of self-tolerance in B cells.

Authors:  A Iglesias
Journal:  Springer Semin Immunopathol       Date:  2001-12

2.  Rituximab add-on therapy for breakthrough relapsing multiple sclerosis: a 52-week phase II trial.

Authors:  R T Naismith; L Piccio; J A Lyons; J Lauber; N T Tutlam; B J Parks; K Trinkaus; S K Song; A H Cross
Journal:  Neurology       Date:  2010-06-08       Impact factor: 9.910

3.  Skewed autoantibody reactivity to the extracellular domain of myelin oligodendrocyte glycoprotein in multiple sclerosis.

Authors:  Maria V Tejada-Simon; Jian Hong; Victor M Rivera; Jingwu Z Zhang
Journal:  Immunology       Date:  2002-12       Impact factor: 7.397

4.  A transgenic model of central nervous system autoimmunity mediated by CD4+ and CD8+ T and B cells.

Authors:  Ana C Anderson; Rucha Chandwaskar; David H Lee; Jenna M Sullivan; Adam Solomon; Roselynn Rodriguez-Manzanet; Bernhard Greve; Raymond A Sobel; Vijay K Kuchroo
Journal:  J Immunol       Date:  2012-01-25       Impact factor: 5.422

Review 5.  Humoral immunity in multiple sclerosis and its animal model, experimental autoimmune encephalomyelitis.

Authors:  Anne H Cross; Jennifer L Stark
Journal:  Immunol Res       Date:  2005       Impact factor: 2.829

Review 6.  B-cells and humoral immunity in multiple sclerosis. Implications for therapy.

Authors:  Sangjin Oh; Cornelia Cudrici; Takahiro Ito; Horea Rus
Journal:  Immunol Res       Date:  2008       Impact factor: 2.829

7.  Elevated intrathecal antibodies against the medium neurofilament subunit in multiple sclerosis.

Authors:  Ales Bartos; Lenka Fialová; Jirina Soukupová; Jaromír Kukal; Ivan Malbohan; Jirí Pit'ha
Journal:  J Neurol       Date:  2007-02-14       Impact factor: 4.849

8.  Regulatory B cells inhibit EAE initiation in mice while other B cells promote disease progression.

Authors:  Takashi Matsushita; Koichi Yanaba; Jean-David Bouaziz; Manabu Fujimoto; Thomas F Tedder
Journal:  J Clin Invest       Date:  2008-10       Impact factor: 14.808

9.  Comprehensive immunophenotyping of cerebrospinal fluid cells in patients with neuroimmunological diseases.

Authors:  Sungpil Han; Yen Chih Lin; Tianxia Wu; Alan D Salgado; Ina Mexhitaj; Simone C Wuest; Elena Romm; Joan Ohayon; Raphaela Goldbach-Mansky; Adeline Vanderver; Adriana Marques; Camilo Toro; Peter Williamson; Irene Cortese; Bibiana Bielekova
Journal:  J Immunol       Date:  2014-02-07       Impact factor: 5.422

Review 10.  [Targeting B cells in multiple sclerosis. Current concepts and strategies].

Authors:  T Menge; H-C Büdingen; M C Dalakas; B C Kieseier; H-P Hartung
Journal:  Nervenarzt       Date:  2009-02       Impact factor: 1.214

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.